Cargando…
COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth
Experience with very mild #COVID19 disease courses in two severe eosinophilic asthmatics with complete eosinophil depletion due to benralizumab treatment counters the recent theories that eosinophilia is protective in COVID-19 infections https://bit.ly/3cnEFvg
Autores principales: | Renner, Andreas, Marth, Katharina, Patocka, Karin, Idzko, Marco, Pohl, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569753/ https://www.ncbi.nlm.nih.gov/pubmed/33257916 http://dx.doi.org/10.1183/23120541.00457-2020 |
Ejemplares similares
-
Dupilumab rapidly improves asthma control in predominantly anti‐IL5/IL5R pretreated Austrian real‐life severe asthmatics
por: Renner, Andreas, et al.
Publicado: (2021) -
Leprosy elimination: A myth busted
por: Yadav, Nidhi, et al.
Publicado: (2014) -
COVID-19 ECMO Myths Busted
por: Sharma, Amita, et al.
Publicado: (2020) -
Source of MDR infections in an ICU: busting the myth
por: Agrawal, R
Publicado: (2015) -
COVID-19 myth-busting: an experimental study
por: Challenger, Aimée, et al.
Publicado: (2022)